https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(22)00376-5/fulltext
0
0
Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, pha - The Lancet
2/17/23 at 11:32pm
Organization
The Lancet
82 words
0
Comments
ZF2001 is safe, well tolerated, and immunogenic in children and adolescents aged 3–17 years. Vaccine-elicited sera can neutralise the omicron BA.2 subvariant, but with reduced activity. The results support further studies of ZF2001 in children and adolescents.
You are the first to view
Create an account or login to join the discussion